既往抗血小板治疗患者的低剂量与标准剂量阿替普酶比较:ENCHANTED试验
ENCHANTED预设亚组分析纳入3285例接受阿替普酶溶栓的急性缺血性卒中患者,其中752例(22.9%)有既往抗血小板治疗史。结果显示,低剂量阿替普酶(0.6 mg/kg)相比标准剂量(0.9 mg/kg)在既往抗血小板治疗患者中可能有更好的结局趋势,但需进一步随机对照试验验证。
要点
- 既往抗血小板治疗患者溶栓后症状性颅内出血风险有升高趋势(OR 1.82,95%CI 1.00-3.30,P=0.051)。
- 低剂量阿替普酶在既往抗血小板治疗患者中可能改善结局(mRS 2-6 OR 0.84,95%CI 0.62-1.12)。
- 该亚组分析结果需进一步随机对照试验验证。
核心结论
- 低剂量阿替普酶可能改善既往抗血小板治疗的急性缺血性卒中溶栓患者的结局,但需进一步随机对照试验验证。
研究设计与样本
- ENCHANTED试验预设亚组分析,纳入3285例接受阿替普酶治疗的急性缺血性卒中患者,随机分配至低剂量(0.6 mg/kg)或标准剂量(0.9 mg/kg)静脉阿替普酶,其中752例(22.9%)有既往抗血小板治疗史。
主要发现
- 调整基线特征和第一周管理因素后,有无既往抗血小板治疗的患者在mRS 2-6(OR 1.01,95%CI 0.81-1.26,P=0.953)、mRS 3-6(OR 0.95,95%CI 0.75-1.20,P=0.662)和序贯mRS移位(OR 1.03,95%CI 0.87-1.21,P=0.770)方面无显著差异。
- 既往抗血小板治疗患者根据SITS-MOST定义的症状性颅内出血有升高趋势(OR 1.82,95%CI 1.00-3.30,P=0.051)。
- 低剂量阿替普酶在既往抗血小板治疗患者中相比无抗血小板治疗患者倾向于更好结局(mRS 2-6 OR 0.84,95%CI 0.62-1.12 vs OR 1.16,95%CI 0.99-1.36),但趋势不显著(P-trend=0.053)。
临床怎么用
- 对于既往使用抗血小板药物的急性缺血性卒中溶栓患者,低剂量阿替普酶可能是一个考虑选项,但需进一步随机对照试验验证。
局限性
- 该分析为预设亚组分析,结果需进一步随机对照试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Many patients receiving thrombolysis for acute ischemic stroke are on prior antiplatelet therapy (APT), which may increase symptomatic intracerebral hemorrhage risk. In a prespecified subgroup analysis, we report comparative effects of different doses of intravenous alteplase according to prior APT use among participants of the international multicenter ENCHANTED study (Enhanced Control of Hypertension and Thrombolysis Stroke Study). METHODS: Among 3285 alteplase-treated patients (mean age, 66.6 years; 38% women) randomly assigned to low-dose (0.6 mg/kg) or standard-dose (0.9 mg/kg) intravenous alteplase within 4.5 hours of symptom onset, 752 (22.9%) reported prior APT use. Primary outcome at 90 days was the combined end point of death or disability (modified Rankin Scale [mRS] scores, 2-6). Other outcomes included mRS scores 3 to 6, ordinal mRS shift, and symptomatic intracerebral hemorrhage by various standard criteria. RESULTS: There were no significant differences in outcome between patients with and without prior APT after adjustment for baseline characteristics and management factors during the first week; defined by mRS scores 2 to 6 (adjusted odds ratio [OR], 1.01; 95% confidence interval [CI], 0.81-1.26; P=0.953), 3 to 6 (OR, 0.95; 95% CI, 0.75-1.20; P=0.662), or ordinal mRS shift (OR, 1.03; 95% CI, 0.87-1.21; P=0.770). Alteplase-treated patients on prior APT had higher symptomatic intracerebral hemorrhage (OR, 1.82; 95% CI, 1.00-3.30; P=0.051) according to the safe implementation of thrombolysis in stroke-monitoring study definition. Although not significant (P-trend, 0.053), low-dose alteplase tended to have better outcomes than standard-dose alteplase in those on prior APT compared with those not using APT (mRS scores of 2-6; OR, 0.84; 95% CI, 0.62-1.12 versus OR, 1.16; 95% CI, 0.99-1.36). CONCLUSIONS: Low-dose alteplase may improve outcomes in thrombolysis-treated acute ischemic stroke patients on prior APT, but this requires further evaluation in a randomized controlled trial. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01422616.
引用
- Robinson TG, Wang X, Arima H, et al. Low- Versus Standard-Dose Alteplase in Patients on Prior Antiplatelet Therapy: The ENCHANTED Trial (Enhanced Control of Hypertension and Thrombolysis Stroke Study). Stroke. 2017. PMID: 28619989. doi:10.1161/STROKEAHA.116.016274
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。